Find public sector tenders

Supply of Lutathera doses for oncological treatment

Meningitis B vaccine supply (2026). Estimated Total Value withheld due to commercial sensitivity (s.94(1)(b)). Publication of this information would be likely to prejudice of commercial interests of the incumbent supplier.

Pneumococcal conjugate vaccine for children (2026). Estimated Total Value withheld due to commercial sensitivity (s.94(1)(b)). Publication of this information would be likely to prejudice of commercial interests of the incumbent supplier.

BCG (tuberculosis) vaccine supply (2027). Estimated Total Value withheld due to commercial sensitivity (s.94(1)(b)). Publication of this information would be likely to prejudice of commercial interests of the incumbent supplier.

Herpes zoster vaccine, inactivated (2027). Estimated Total Value withheld due to commercial sensitivity (s.94(1)(b)). Publication of this information would be likely to prejudice of commercial interests of the incumbent supplier.

Meningococcal ACWY vaccine supply (2027). Estimated Total Value withheld due to commercial sensitivity (s.94(1)(b)). Publication of this information would be likely to prejudice of commercial interests of the incumbent supplier.

The provision of Measles, Mumps, Rubella and Varicella (MMRV) vaccine to be used as part of the national immunisation programme

NULL

NULL

The UK Health Security Agency (UKHSA) wishes to establish a contract with a supplier for the provision of a central supply of Rabies vaccine (pre and post exposure), commencing from 1 February 2026 for the UK.